drugset / Trial / NCT06211114
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.
Timeline
- Start
- 2024-02-09
- Primary completion
- 2026-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 5 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tirelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |